LUC00261I2 - - Google Patents

Download PDF

Info

Publication number
LUC00261I2
LUC00261I2 LU00261C LUC00261C LUC00261I2 LU C00261 I2 LUC00261 I2 LU C00261I2 LU 00261 C LU00261 C LU 00261C LU C00261 C LUC00261 C LU C00261C LU C00261 I2 LUC00261 I2 LU C00261I2
Authority
LU
Luxembourg
Application number
LU00261C
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of LUC00261I2 publication Critical patent/LUC00261I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
LU00261C 2013-02-22 2022-05-13 LUC00261I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767947P 2013-02-22 2013-02-22
PCT/IB2014/058889 WO2014128591A1 (fr) 2013-02-22 2014-02-11 Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)

Publications (1)

Publication Number Publication Date
LUC00261I2 true LUC00261I2 (fr) 2025-04-25

Family

ID=50151346

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00261C LUC00261I2 (fr) 2013-02-22 2022-05-13

Country Status (48)

Country Link
US (3) US9035074B2 (fr)
EP (2) EP2958921B1 (fr)
JP (2) JP6145179B2 (fr)
KR (1) KR101787858B1 (fr)
CN (2) CN107089985B (fr)
AP (1) AP2015008664A0 (fr)
AR (1) AR094857A1 (fr)
AU (1) AU2014220357B2 (fr)
BR (1) BR112015019634B1 (fr)
CA (1) CA2900703C (fr)
CL (1) CL2015002303A1 (fr)
CR (1) CR20150395A (fr)
CU (1) CU24275B1 (fr)
CY (3) CY1119502T1 (fr)
DK (2) DK3290421T3 (fr)
DO (1) DOP2015000206A (fr)
EA (1) EA027879B1 (fr)
ES (2) ES2713052T3 (fr)
FR (1) FR22C1006I2 (fr)
GE (1) GEP201606600B (fr)
HR (2) HRP20171599T2 (fr)
HU (3) HUE041778T2 (fr)
IL (1) IL240132B (fr)
LT (3) LT2958921T (fr)
LU (1) LUC00261I2 (fr)
MA (1) MA38347A1 (fr)
MD (1) MD4735C1 (fr)
ME (2) ME03301B (fr)
MX (1) MX374338B (fr)
MY (1) MY177476A (fr)
NL (1) NL301155I2 (fr)
NO (2) NO3052752T3 (fr)
NZ (1) NZ710411A (fr)
PE (1) PE20151764A1 (fr)
PH (1) PH12015501779A1 (fr)
PL (2) PL2958921T3 (fr)
PT (2) PT2958921T (fr)
PY (1) PY1407086A (fr)
RS (2) RS58245B1 (fr)
SG (1) SG11201505816UA (fr)
SI (2) SI2958921T1 (fr)
TN (1) TN2015000355A1 (fr)
TR (1) TR201902525T4 (fr)
TW (1) TWI507408B (fr)
UA (1) UA111804C2 (fr)
UY (1) UY35337A (fr)
WO (1) WO2014128591A1 (fr)
ZA (1) ZA201505454B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2605652B1 (fr) 2010-08-18 2017-11-08 Samumed, LLC Dicétones et hydroxydicétones utiles en tant qu'activateurs de la voie de signalisation de la caténine
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
ES2709824T3 (es) 2013-02-22 2019-04-17 Samumed Llc Gamma-dicetonas como activadores de la ruta de señalización Wnt/beta-catenina
RS58245B1 (sr) 2013-02-22 2019-03-29 Pfizer Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak)
EP3180344B1 (fr) * 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
UA118822C2 (uk) * 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
KR20250010141A (ko) 2015-10-16 2025-01-20 애브비 인코포레이티드 (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
JP7096592B2 (ja) * 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
CN112384282B (zh) * 2018-07-06 2024-07-02 辉瑞公司 吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途
MX2021005334A (es) * 2018-11-05 2021-06-23 Avista Pharma Solutions Inc Compuestos quimicos.
FI3915989T3 (fi) 2019-01-30 2023-09-20 Felicamed Biotechnology Co Ltd Jak:n estäjä ja sen valmistusmenetelmä
SG11202108863WA (en) 2019-02-15 2021-09-29 Pfizer Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
EP3939979A4 (fr) 2019-03-14 2022-04-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Inhibiteur de kinase jak, son procédé de préparation et ses applications dans le domaine de la médecine
EP3989975A4 (fr) * 2019-06-27 2023-09-27 Glenmark Life Sciences Limited Procédé pour la préparation d'abrocitinib
EP4028007B1 (fr) 2019-09-11 2025-03-26 Pfizer Inc. Traitement de l'hidradénite suppurée avec un inhibiteur de jak
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
WO2021198980A1 (fr) 2020-04-04 2021-10-07 Pfizer Inc. Procédés de traitement de la maladie à coronavirus 2019
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
CA3177830A1 (fr) 2020-05-13 2021-11-18 Maria BECONI Anticorps anti-hemojuveline (hjv) pour le traitement de la myelofibrose
KR20230015989A (ko) * 2020-05-28 2023-01-31 화이자 인코포레이티드 피롤로[2,3-d]피리미딘 유도체
TW202227434A (zh) * 2020-09-08 2022-07-16 瑞士商葛德瑪控股公司 新穎jak抑制劑化合物、其合成方法及其用途
EP4210828A1 (fr) * 2020-09-11 2023-07-19 Galderma Holding SA Nouveaux composés inhibiteurs de jak, leur procédé de synthèse et leur utilisation
WO2022167913A1 (fr) 2021-02-02 2022-08-11 Pfizer Inc. Régime posologique pour le traitement de l'eczéma de la main chronique
KR20230019801A (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN118255769A (zh) * 2022-12-28 2024-06-28 格格巫（珠海）生物科技有限公司 一种立体异构体的制备方法及中间体
ES2993658B2 (es) 2023-06-27 2025-07-02 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
WO2025008772A2 (fr) 2023-07-06 2025-01-09 Pfizer Ireland Pharmaceuticals Procédé de fabrication amélioré et intermédiaires pour un composé pyrrolo[2,3-d]pyrimidine et leur utilisation
ES3040374A1 (es) 2024-04-30 2025-10-30 Moehs Iberica Sl Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
US6765008B1 (en) 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
JPH06329674A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH06329675A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH08134068A (ja) 1994-11-02 1996-05-28 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
TW505646B (en) * 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (fr) 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
EP1175421A1 (fr) 1999-04-30 2002-01-30 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
PL359563A1 (pl) 2000-06-26 2004-08-23 Pfizer Products Inc. Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004032834A2 (fr) 2002-10-04 2004-04-22 Merck & Co., Inc. Inhibiteurs de thrombine
KR100678800B1 (ko) 2002-11-21 2007-02-05 화이자 프로덕츠 인코포레이티드 3-아미노-피페리딘 유도체 및 그의 제조 방법
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2614907C (fr) * 2005-07-29 2012-02-28 Pfizer Products Inc. Derives de pyrrolo[2,3-d]pyrimidine, leurs intermediaires et leur synthese
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009531443A (ja) 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
AU2008323694A1 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
EP2209771A1 (fr) 2007-11-08 2010-07-28 Pfizer, Inc. Dérivés d'acide cyclobutylcarboxylique
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
EP2384326B1 (fr) * 2008-08-20 2014-04-23 Zoetis LLC Composés pyrrolo[2,3-d]pyrimidines
AU2009294290B2 (en) 2008-09-18 2012-08-30 Pfizer Limited Amide compounds useful in therapy
EA201290147A1 (ru) * 2009-10-15 2012-11-30 Пфайзер Инк. Пирроло[2,3-d]пиримидиновые соединения
ME02800B (fr) 2009-12-01 2018-01-20 Abbvie Inc Composés tricycliques innovants
WO2011075334A1 (fr) * 2009-12-18 2011-06-23 Pfizer Inc. Composés pyrrolo[2,3-d]pyrimidines
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2012009798A (es) 2010-02-24 2012-09-12 Pfizer Composiciones veterinarias.
WO2012009649A1 (fr) 2010-07-16 2012-01-19 Anderson Gaweco Inhibiteurs mif et leurs utilisations
WO2012009678A1 (fr) 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Compositions thérapeutiquement actives et méthode d'utilisation correspondante
CA2819648C (fr) 2010-12-03 2018-05-01 Epizyme, Inc. Composes purines et 7-deazapurines substituees en tant que modulateurs d'enzymes epigeniques
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
US20140057895A1 (en) 2011-06-07 2014-02-27 Kazuhiro Mizuno Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
DK2796460T3 (en) * 2011-12-21 2018-08-27 Jiangsu Hengrui Medicine Co SEXUAL PYRROL HETEROARYL RING DERIVATIVES, METHOD OF PREPARATION AND MEDICAL APPLICATIONS THEREOF
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20150028299A (ko) 2012-07-20 2015-03-13 조에티스 엘엘씨 야누스 키나제 (ｊａｋ) 억제제 투여요법
JP2014133739A (ja) 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
RS58245B1 (sr) * 2013-02-22 2019-03-29 Pfizer Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak)
EP3180344B1 (fr) 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase

Also Published As

Publication number Publication date
HRP20171599T1 (hr) 2017-12-01
CN107089985A (zh) 2017-08-25
MD4735C1 (ro) 2021-07-31
NL301155I2 (nl) 2022-02-23
PT2958921T (pt) 2017-11-20
MX374338B (es) 2025-03-06
JP2017165762A (ja) 2017-09-21
PT3290421T (pt) 2019-03-01
LT3290421T (lt) 2019-02-25
BR112015019634A2 (pt) 2019-12-17
PL3290421T3 (pl) 2019-05-31
HRP20171599T2 (hr) 2018-11-16
HUE041778T2 (hu) 2019-05-28
SI2958921T1 (sl) 2017-12-29
SI3290421T1 (sl) 2019-03-29
US9035074B2 (en) 2015-05-19
US9549929B2 (en) 2017-01-24
CY1119502T1 (el) 2018-03-07
NO2022004I1 (no) 2022-02-01
US20150246048A1 (en) 2015-09-03
LTC2958921I2 (fr) 2024-03-25
TWI507408B (zh) 2015-11-11
KR101787858B1 (ko) 2017-10-18
PY1407086A (es) 2017-10-02
MY177476A (en) 2020-09-16
PH12015501779B1 (en) 2015-12-02
ME02904B (fr) 2018-04-20
AU2014220357A1 (en) 2015-08-06
CA2900703A1 (fr) 2014-08-28
EA027879B1 (ru) 2017-09-29
HK1213881A1 (zh) 2016-07-15
CN107089985B (zh) 2019-06-07
JP2016509049A (ja) 2016-03-24
AU2014220357B2 (en) 2017-04-27
TR201902525T4 (tr) 2019-03-21
TW201443055A (zh) 2014-11-16
IL240132A0 (en) 2015-09-24
JP6145179B2 (ja) 2017-06-07
EP3290421A1 (fr) 2018-03-07
LTPA2022502I1 (fr) 2022-03-10
MA38347A1 (fr) 2017-10-31
US9545405B2 (en) 2017-01-17
ES2713052T3 (es) 2019-05-17
FR22C1006I1 (fr) 2022-03-25
CU24275B1 (es) 2017-10-05
CU20150078A7 (es) 2016-01-29
BR112015019634B1 (pt) 2022-09-20
KR20150109434A (ko) 2015-10-01
LT2958921T (lt) 2017-11-27
US20140243312A1 (en) 2014-08-28
RS56503B1 (sr) 2018-02-28
ZA201505454B (en) 2016-07-27
CN105008362A (zh) 2015-10-28
EP2958921B1 (fr) 2017-09-20
ME03301B (fr) 2019-07-20
HUS2200003I1 (hu) 2022-02-28
EP3290421B1 (fr) 2019-01-02
FR22C1006I2 (fr) 2023-01-27
MX2015010928A (es) 2015-10-29
CR20150395A (es) 2015-09-23
RS58245B1 (sr) 2019-03-29
CN105008362B (zh) 2017-06-06
CA2900703C (fr) 2017-11-28
TN2015000355A1 (fr) 2017-01-03
HUE037192T2 (hu) 2018-08-28
CY2022003I1 (el) 2022-03-24
CY2022003I2 (el) 2022-03-24
PH12015501779A1 (en) 2015-12-02
EA201591255A1 (ru) 2016-03-31
CY1121468T1 (el) 2020-05-29
IL240132B (en) 2020-09-30
ES2647525T3 (es) 2017-12-22
DK3290421T3 (en) 2019-03-18
DOP2015000206A (es) 2016-02-15
AR094857A1 (es) 2015-09-02
NO3052752T3 (fr) 2018-06-16
MD4735B1 (ro) 2020-12-31
HRP20190152T1 (hr) 2019-03-22
WO2014128591A1 (fr) 2014-08-28
CL2015002303A1 (es) 2015-12-18
UY35337A (es) 2014-09-30
AP2015008664A0 (en) 2015-08-31
US20150225408A1 (en) 2015-08-13
EP2958921A1 (fr) 2015-12-30
PE20151764A1 (es) 2015-12-03
SG11201505816UA (en) 2015-09-29
DK2958921T3 (da) 2017-11-06
NZ710411A (en) 2017-11-24
NL301155I1 (fr) 2021-12-22
UA111804C2 (uk) 2016-06-10
GEP201606600B (en) 2017-01-10
PL2958921T3 (pl) 2018-01-31
MD20150073A2 (ro) 2016-01-31

Similar Documents

Publication Publication Date Title
LTC2958921I2 (fr)
AP2016009275A0 (fr)
BR112016014396A2 (fr)
BR112016010555A2 (fr)
BR112016008376A2 (fr)
BR112015007533A2 (fr)
BR102016010778A2 (fr)
BR112014018502A2 (fr)
BR112014019326A2 (fr)
BR112014018516A2 (fr)
BR112014018480A2 (fr)
BR112014020341A2 (fr)
BR112014021878A2 (fr)
BR112016013340A2 (fr)
BR112016007704A2 (fr)
BR112016005705A2 (fr)
BR112014018468A2 (fr)
BR112014019204A2 (fr)
BR112016000627A2 (fr)
BR112015015948A2 (fr)
BR112014018578A2 (fr)
BR112014018483A2 (fr)
BR112016011906A2 (fr)
BR112015015312A2 (fr)
BR112014024039A2 (fr)